Nathan Connell on the 1st von Willebrand Factor/Factor VIII Relevance Academy
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared on LinkedIn:
”We recently held the first von Willebrand Factor/Factor VIII Relevance Academy in Orlando, Florida.
It was a wonderful day of learning and discussion about so many topics of importance to the hemostasis community.
From basic science to clinical and epidemiologic applications, I was excited to see so much focus on improving the quality of life for those with inherited bleeding disorders.
I was asked to present on the role of VWF concentrate prophylaxis in people with von Willebrand disease.
We have more data now than we did when the international VWD guidelines were published in 2021.
Still, we continue to have so many questions about who would benefit the most and how to optimize our prophylaxis strategies.
Thank you to the always outstanding Octapharma team, including Stefano Carta, Belyanskaya Larisa, Claudio Sandoval, and many others, as well as Academy chair Robert Sidonio, and all the faculty and participants who contributed to the discussion.”
Stay updated with Hemostasis Today.
-
Jan 13, 2026, 13:03Claudio Laudani on Dual Versus Single Antiplatelet Therapy
-
Jan 13, 2026, 12:46Stephanie Carlin and Colleagues on Clinical Outcomes of DOAC-Anticonvulsant Coprescription
-
Jan 13, 2026, 10:53Lena Volland on Ming Y Lim’s Example of Designing Care Models for WGBD Community With Intention
-
Jan 13, 2026, 05:05Pablo Corral Shares Key Takeaways on Reducing LDL-Cholesterol to Very Low Levels
-
Jan 13, 2026, 04:49Martin Haluzík Shares A Study on GLP1-1RAs Use in Peripheral Artery Disease and DM
-
Jan 13, 2026, 04:37Shreya Agarwal and Bryce A Kerlin on The Impact of Advanced Hemostasis and Thrombosis Fellowship Trainings
-
Jan 13, 2026, 03:53Christian Schulze Shares New Data from DANGERSHOCK
-
Jan 13, 2026, 03:39Samwel Mikaye Breaks Down Peripheral Blood Smear
-
Jan 12, 2026, 20:15Mazou Ngou Temgoua on SCAF: Subclinical Atrial Fibrillation on Treatment with Apixaban or Aspirin